68 Ga-FAPI-04 PET/CT and 18 F-FDG PET/CT in Metastatic Papillary Renal Cell Cancer

Clin Nucl Med. 2023 May 1;48(5):e223-e224. doi: 10.1097/RLU.0000000000004587. Epub 2023 Feb 8.

Abstract

Papillary renal cell cancer is a rare malignancy with limited treatment options in the advanced stage of the disease. We present the case of a 62-year-old man with progressive left-sided papillary renal cell carcinoma who underwent 68 Ga-FAPI (fibroblast activated protein inhibitor)-04 and 18 F-FDG PET/CT imaging. 68 Ga-FAPI-04 PET/CT demonstrated variable FAP expression in all metastatic lesions detected by 18 F-FDG PET/CT, including multiple lymph nodes, bone, and thyroid. This case highlights that FAP-targeted imaging can be a promising modality for diagnostic and theranostic use in papillary renal cell carcinoma.

Publication types

  • Case Reports

MeSH terms

  • Carcinoma, Renal Cell* / diagnostic imaging
  • Fluorodeoxyglucose F18
  • Gallium Radioisotopes
  • Humans
  • Kidney Neoplasms* / diagnostic imaging
  • Male
  • Middle Aged
  • Positron Emission Tomography Computed Tomography

Substances

  • 68Ga-FAPI
  • Fluorodeoxyglucose F18
  • Gallium-68
  • Gallium Radioisotopes